

# CITATION REPORT

List of articles citing

**Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group**

**DOI: 10.1002/mds.870130111**  
**Movement Disorders, 1998, 13, 39-45.**

**Source:** <https://exaly.com/paper-pdf/29040008/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
252	Maladie de Parkinson Vers un mēanisme de mort neuronale. <b>1997</b> , 14, 25-45		62
251	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. <i>Movement Disorders</i> , <b>1998</b> , 13, 46-51	7	115
250	The impact of ropinirole on blood pressure and noradrenaline concentration after active orthostasis in Parkinsonian patients. <i>Parkinsonism and Related Disorders</i> , <b>1998</b> , 4, 61-3	3.6	9
249	Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. <i>Parkinsonism and Related Disorders</i> , <b>1998</b> , 4, 183-8	3.6	7
248	New developments in understanding the etiology of Parkinson's disease and in its treatment. <b>1998</b> , 8, 783-90		74
247	Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. <b>1998</b> , 44, S115-20		259
246	Parkinson's disease. First of two parts. <b>1998</b> , 339, 1044-53		1636
245	Dopamine Agonists in Parkinson's Disease. <i>CNS Drugs</i> , <b>1998</b> , 10, 159-170	6.7	9
244	Should treatment of Parkinson's disease be started with a dopamine agonist?. <b>1998</b> , 51, S21-4		28
243	Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. <b>1999</b> , 19, 9821-30		291
242	A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. <b>1999</b> , 53, 364-70		119
241	Ropinirole in the treatment of Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>1999</b> , 8, 697-710		3
240	The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. <b>1999</b> , 47, 219-22		13
239	ESR characterization and metalokinetic analysis of Cr(V) in the blood of rats given carcinogen chromate(VI) compounds. <b>1999</b> , 76, 71-80		27
238	Metal ion transporters in mammals: structure, function and pathological implications. <b>1999</b> , 518, 1-12		71
237	The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. <b>1999</b> , 890, 7-25		76
236	Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. <b>1999</b> , 55, 299-303		15

235	[High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero]. <b>1999</b> , 70, 742-4		1
234	The initial treatment of Parkinson's disease should begin with levodopa. <i>Movement Disorders</i> , <b>1999</b> , 14, 716-24	7	56
233	Treatment of Parkinson's disease should begin with a dopamine agonist. <i>Movement Disorders</i> , <b>1999</b> , 14, 725-30	7	91
232	Depression in patients with Parkinson's disease. <b>1999</b> , 14, 711-718		130
231	Dopamine agonists. <b>1999</b> , 83, 415-43, vi-vii		35
230	Abnormal performance on the PD test battery by asymptomatic first-degree relatives. <b>1999</b> , 52, 757-62		82
229	FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. <b>1999</b> , 19, 3440-7		369
228	Ropinirole and pramipexole, the new agonists. <b>1999</b> , 26 Suppl 2, S27-33		38
227	Treatment of early Parkinson's disease. <b>1999</b> , 26 Suppl 2, S39-44		4
226	Treatment of early Parkinson's disease. <b>2000</b> , 321, 1-2		41
225	The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. <b>2000</b> , 20, 9207-14		366
224	A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. <i>Clinical Neuropharmacology</i> , <b>2000</b> , 23, 34-44	1.4	92
223	Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. <i>Clinical Neuropharmacology</i> , <b>2000</b> , 23, 252-61	1.4	26
222	The initial treatment of Parkinson's disease. <i>Movement Disorders</i> , <b>2000</b> , 15, 360-1	7	15
221	Treatment of Parkinson's disease should begin with a dopamine agonist. <i>Movement Disorders</i> , <b>2000</b> , 15, 361-2	7	4
220	Author's reply. <i>Movement Disorders</i> , <b>2000</b> , 15, 362-362	7	
219	Cortical and brain stem hyperexcitability in a pathologically confirmed case of multiple system atrophy. <i>Movement Disorders</i> , <b>2000</b> , 15, 362-3	7	16
218	Hemifacial spasm and hypertension: how strong is the association?. <i>Movement Disorders</i> , <b>2000</b> , 15, 363-57		15

217	Authors' reply. <i>Movement Disorders</i> , <b>2000</b> , 15, 364-365	7	
216	Mycophenolate in the prevention of recurrent neutralizing botulinum toxin A antibodies in cervical dystonia. <i>Movement Disorders</i> , <b>2000</b> , 15, 365-6	7	7
215	Atypical and typical cranial dystonia following dental procedures. <i>Movement Disorders</i> , <b>2000</b> , 15, 366	7	3
214	Pramipexole-induced somnolence and episodes of daytime sleep. <i>Movement Disorders</i> , <b>2000</b> , 15, 658-637		187
213	Endogenous dopaminergic tone and dopamine agonist action. <i>Movement Disorders</i> , <b>2000</b> , 15, 804-12	7	7
212	The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates. <b>2000</b> , 129, 1355-64		14
211	Clinical pharmacology of dopamine agonists. <b>2000</b> , 20, 17S-25S		14
210	5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. <b>2000</b> , 398, 59-64		35
209	Antioxidant strategy to counteract the side effects of antipsychotic therapy: an in vivo study in rats. <b>2000</b> , 408, 35-9		4
208	[1st long-term double-blind study of effectiveness and dyskinesia prevention of ropinirol]. <b>2000</b> , 71, 1012-4		1
207	The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. <i>Journal of Neurology</i> , <b>2000</b> , 247 Suppl 2, II51-7	5.5	22
206	Der Non-Ergot-Agonist Ropinirol bei Morbus Parkinson. <b>2000</b> , 27, 318-324		
205	Pharmacological treatment of Parkinson's disease. <b>2000</b> , 76, 602-10		26
204	Dopamine agonists: their role in the treatment of Parkinson's disease. <b>2000</b> , 68, 685-9		79
203	Is levodopa toxic?. <b>2000</b> , 57, 408-10		16
202	Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. <b>2000</b> , 41, 181-9		70
201	NADH-ferric reductase activity associated with dihydropteridine reductase. <b>2000</b> , 271, 788-95		8
200	Nitric oxide, glial cells and neuronal degeneration in parkinsonism. <b>2000</b> , 21, 163-5		49

199	Metabolism and functions of glutathione in brain. <i>Progress in Neurobiology</i> , <b>2000</b> , 62, 649-71	10.9	1282
198	Treatment of Parkinson's disease. <b>2000</b> , 7, 484-94		16
197	Molecular mechanism of monoamine toxicity in Parkinson's disease: hypothetical cell death model. <b>2000</b> , 54, 269-74		12
196	Treatment of early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2000</b> , 7, 59-62	3.6	5
195	The lactate-dependent enhancement of hydroxyl radical generation by the Fenton reaction. <b>2000</b> , 32, 429-38		48
194	Early Parkinson's disease: what is the best approach to treatment. <b>2000</b> , 17, 165-81		20
193	Maladie de Parkinson. <b>2000</b> , 11, 25-45		
192	Clinical pharmacokinetics of ropinirole. <b>2000</b> , 39, 243-54		115
191	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <b>2000</b> , 342, 1484-91		1253
190	Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. <b>2001</b> , 24, 863-8		45
189	Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. <b>2001</b> , 169, 219-30		177
188	Age-related structural changes in the human midbrain: an MR image study. <i>Neurobiology of Aging</i> , <b>2001</b> , 22, 595-601	5.6	16
187	Iron and neurodegenerative disorders. <b>2001</b> , 55, 155-64		200
186	Neuroprotective effects of D3 dopamine receptor agonists. <i>Parkinsonism and Related Disorders</i> , <b>2001</b> , 7, 213-223	3.6	58
185	Daytime somnolence in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2001</b> , 7, 283-286	3.6	30
184	Economic and health-related quality of life considerations of new therapies in Parkinson's disease. <b>2001</b> , 19, 729-52		36
183	Natural-resistance-associated macrophage protein 1 is an H <sup>+</sup> /bivalent cation antiporter. <b>2001</b> , 354, 511-9		102
182	Treatment of PC12 cells with nerve growth factor increases iron uptake. <b>2001</b> , 357, 881-6		6

181	Treatment of PC12 cells with nerve growth factor increases iron uptake. <b>2001</b> , 357, 881-886		11
180	Natural-resistance-associated macrophage protein 1 is an H <sup>+</sup> /bivalent cation antiporter. <b>2001</b> , 354, 511-519		176
179	Chapter 9 Clinical Trials in Parkinson's Disease. <b>2001</b> , 173-199		
178	Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists. <b>2001</b> , 3, 479-493		9
177	Initial treatment of early Parkinson's disease: a review of recent, randomized controlled trials. <b>2001</b> , 1, 329-36		3
176	Nramp1 is expressed in neurons and is associated with behavioural and immune responses to stress. <b>2001</b> , 3, 69-78		26
175	SLC11A1 (formerly NRAMP1) and disease resistance. <b>2001</b> , 3, 773-84		199
174	Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. <i>Movement Disorders</i> , <b>2001</b> , 16, 448-58	7	950
173	Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets ( <i>Callithrix jacchus</i> ). <i>Movement Disorders</i> , <b>2001</b> , 16, 631-41	7	78
172	Effects of fetal bovine serum on ferrous ion-induced oxidative stress in pheochromocytoma (PC12) cells. <b>2001</b> , 26, 407-14		5
171	Treatment options for depression and psychosis in Parkinson's disease. <i>Journal of Neurology</i> , <b>2001</b> , 248 Suppl 3, III12-21	5.5	30
170	Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. <b>2001</b> , 61, 73-85		31
169	Neuronal Death by Accident or by Design. <b>2001</b> ,		
168	Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?. <b>2001</b> , 10, 1853-8		46
167	An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. <b>2001</b> , 56, S1-S88		443
166	Dopamine agonists. <b>2001</b> , 21, 9-14		6
165	Clinical trial end points: on the road to nowhere?. <b>2002</b> , 58, 679-86		32
164	Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. <b>2002</b> , 161, 2087-98		124

163	Brain iron metabolism and neurodegenerative disorders. <b>2002</b> , 24, 188-96		73
162	'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?. <b>2002</b> , 25, 473-83		33
161	Benefit-risk considerations in the treatment of dementia with Lewy bodies. <b>2002</b> , 25, 511-23		14
160	Treatment interventions for Parkinson's disease: an evidence based assessment. <b>2002</b> , 359, 1589-98		221
159	The management of patients with early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2002</b> , 9, 61-7	3.6	14
158	The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. <b>2002</b> , 327, 91-4		48
157	Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17, 1302-4	7	5
156	Levodopa: management of Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17 Suppl 4, S23-37	7	5
155	DA agonists -- non-ergot derivatives: ropinirole: management of Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17 Suppl 4, S98-102	7	5
154	Drugs to treat dementia and psychosis: management of Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17 Suppl 4, S120-7	7	11
153	Intrastriatal iron perfusion releases dopamine: an in-vivo microdialysis study. <i>Journal of Neural Transmission</i> , <b>2002</b> , 109, 645-9	4.3	4
152	Dosing with ropinirole in a clinical setting. <i>Acta Neurologica Scandinavica</i> , <b>2002</b> , 106, 200-4	3.8	13
151	Impact of endogenous nitric oxide on microglial cell energy metabolism and labile iron pool. <b>2002</b> , 81, 615-23		40
150	Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. <b>2002</b> , 83, 320-30		92
149	Measurements in vivo of parameters pertinent to ROS/RNS using EPR spectroscopy. <b>2002</b> , 234/235, 341-357		39
148	Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. <b>2003</b> , 984, 224-32		81
147	Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. <b>2003</b> , 71, 46-63		133
146	Neuroinflammatory processes in Parkinson's disease. <b>2003</b> , 53 Suppl 3, S49-58; discussion S58-60		298

145	Limitations of current Parkinson's disease therapy. <b>2003</b> , 53 Suppl 3, S3-12; discussion S12-5		191
144	Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases. <b>2003</b> , 1651, 116-23		64
143	Clinical criteria for the switch of treatment strategies in Parkinson's disease. <b>2003</b> , 105, 241-4		1
142	Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. <b>2003</b> , 26, 439-44		64
141	The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2003</b> , 9, 131-7	3.6	89
140	Agonists vs levodopa in PD: the thrill of witha. <b>2003</b> , 60, 360-2		33
139	Metals Distribution and Regionalization in the Brain. <b>2003</b> , 15-65		7
138	CJN volume 30 issue 1 Cover and Front matter. <b>2003</b> , 30, f1-f32		
137	Pharmacological Management of Parkinson's Disease. <b>2004</b> , 34, 229-232		6
136	Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. <b>2004</b> , 1013, 51-9		67
135	Dopamine receptor agonists in the therapy of Parkinson's disease. <i>Journal of Neural Transmission</i> , <b>2004</b> , 111, 1375-446	4.3	67
134	Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system. <b>2004</b> , 29, 2239-43		33
133	Accelerated $\alpha$ -synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. <b>2004</b> , 1013, 51-51		
132	Psychosis in Nursing Home Patients With Parkinson's Disease. <i>Journal of the American Medical Directors Association</i> , <b>2004</b> , 5, 167-173	5.9	10
131	Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. <b>2004</b> , 75, 2539-49		268
130	Role of transient receptor potential canonical 6 (TRPC6) in non-transferrin-bound iron uptake in neuronal phenotype PC12 cells. <b>2004</b> , 378, 975-82		47
129	Structural changes in the midbrain with aging and Parkinson's disease: an MRI study. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 449-53	5.6	17
128	Brain Iron as an Endogenous Contrast Agent in High-Field MRI. <b>2005</b> , 44-61		2

127	Glia cell number modulates sensitivity to MPTP in mice. <b>2005</b> , 52, 144-52		47
126	Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 1397-404	7	70
125	Suboptimal medication adherence in Parkinson's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 1502-7	7	155
124	Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. <i>Journal of Neural Transmission</i> , <b>2005</b> , 112, 1237-48	4.3	75
123	Bis-(hydroxyamino)triazines: highly stable hydroxylamine-based ligands for iron(III) cations. <b>2005</b> , 5319-21		19
122	Electron tomography of degenerating neurons in mice with abnormal regulation of iron metabolism. <b>2005</b> , 150, 144-53		51
121	Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. <b>2005</b> , 156, 173-9		41
120	Neuroinflammatory processes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2005</b> , 11 Suppl 1, S9-S15	3.6	154
119	Bis(hydroxyamino)triazines: versatile and high-affinity tridentate hydroxylamine ligands for selective iron(III) chelation. <b>2006</b> , 1285-93		24
118	Existing dopaminergic therapies for Parkinson's disease. <b>2006</b> , 16, 1613-1625		12
117	Prevalence of haemochromatosis gene mutations in Parkinson's disease. <b>2007</b> , 78, 315-7		33
116	Iron and ferritin in hippocampal cortex and substantia nigra in human brain—implications for the possible role of iron in dementia. <b>2006</b> , 248, 31-4		11
115	Method Development and Validation of a Rapid Determination of Ropinirole in Tablets by LC-UV. <b>2006</b> , 64, 459-461		11
114	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. <i>Journal of Neurology</i> , <b>2006</b> , 253, 1633-9	5.5	20
113	Clinical studies with ropinirole in Parkinson's disease and RLS. <i>Journal of Neurology</i> , <b>2006</b> , 253 Suppl 4, IV16-21	5.5	1
112	Scales in Parkinson's disease. <i>Journal of Neurology</i> , <b>2006</b> , 253 Suppl 4, IV32-5	5.5	34
111	Defining a minimal clinically relevant difference for the unified Parkinson's rating scale: an important but still unmet need. <i>Movement Disorders</i> , <b>2006</b> , 21, 1059-61	7	31
110	Minimal clinically important change on the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , <b>2006</b> , 21, 1200-7	7	218

109	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , <b>2006</b> , 21, 1844-50	116
108	Brain Repair. <i>Advances in Experimental Medicine and Biology</i> , <b>2006</b> ,	3.6 2
107	Measuring therapy adherence in Parkinson's disease: a comparison of methods. <b>2006</b> , 77, 249-51	46
106	Parkinson's disease: genetics and beyond. <b>2007</b> , 5, 99-113	20
105	[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy]. <b>2007</b> , 75, 236-41	11
104	Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations. <b>2007</b> , 55, 629-31	16
103	Methamphetamine increases basal ganglia iron to levels observed in aging. <b>2007</b> , 18, 1741-5	22
102	Dopamine agonists. <b>2007</b> , 84, 73-92	4
101	Parkinson's Disease. <b>2007</b> ,	
100	Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study. <i>Movement Disorders</i> , <b>2007</b> , 22, 1860-5	7 34
99	Low plasma uric acid level in Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 1133-7	7 100
98	Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model. <b>2008</b> , 8, 4822-32	74
97	Paradoxical aspects of parkinsonian tremor. <i>Movement Disorders</i> , <b>2008</b> , 23, 168-73	7 81
96	Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. <b>2008</b> , 49, 446-54	174
95	Regional distribution of tetrahydroisoquinoline derivatives in rodent, human, and Parkinson's disease brain. <b>2008</b> , 107, 1398-413	30
94	Systemic administration of Zn <sup>2+</sup> during the reperfusion phase of transient cerebral ischaemia protects rat hippocampus against iron-catalysed postischaemic injury. <b>2008</b> , 35, 775-81	10
93	Neurodegenerative Diseases. <b>2008</b> , 565-588	0
92	Neuroprotection by <i>Spirulina platensis</i> protean extract and phycocyanin against iron-induced toxicity in SH-SY5Y neuroblastoma cells. <b>2008</b> , 22, 1496-502	76

91	Outcomes associated with pharmacologic treatments in Parkinson's disease: a review of recent literature. <b>2008</b> , 9, 163-74		5
90	[The development of therapeutic agents for Parkinson's disease and problems in their clinical application]. <b>2008</b> , 131, 281-4		
89	The scientific and clinical basis for the treatment of Parkinson disease (2009). <b>2009</b> , 72, S1-136		547
88	Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease. <b>2009</b> , 29, 1452-67		40
87	Iron transport across biologic membranes. <b>1999</b> , 57, 114-23		60
86	Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. <b>2009</b> , 14, 324-9		105
85	Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. <b>2009</b> , 14, 372-8		103
84	Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. <b>2009</b> , 16, 879-95		281
83	Impact of Magnetic Labeling on Human and Mouse Stem Cells and Their Long-Term Magnetic Resonance Tracking in a Rat Model of Parkinson Disease. <b>2009</b> , 8, 7290.2009.00017		20
82	Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats. <b>2000</b> , 52, 1129-35		14
81	Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. <b>2010</b> , 84, 825-89		292
80	The effect of electroacupuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum. <b>2010</b> , 60, 27-34		40
79	Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. <b>2010</b> , 58, 588-98		242
78	Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. <i>Movement Disorders</i> , <b>2010</b> , 25, 474-80	7	63
77	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 2326-32	7	30
76	Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. <b>2010</b> , 113, 454-64		60
75	The clinically important difference on the unified Parkinson's disease rating scale. <b>2010</b> , 67, 64-70		317
74	Multiple sclerosis and the accumulation of iron in the Basal Ganglia: quantitative assessment of brain iron using MRI t(2) relaxometry. <b>2010</b> , 63, 136-43		41

73	Therapy adherence issues in Parkinson's disease. <b>2010</b> , 289, 115-8		36
72	Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. <b>2010</b> , 33, 147-61		60
71	mRNA expression of proteins involved in iron homeostasis in brain regions is altered by age and by iron overloading in the neonatal period. <b>2010</b> , 35, 564-71		55
70	Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. <i>CNS Drugs</i> , <b>2010</b> , 24, 941-68	6.7	79
69	Striatal dopamine depletion induces forelimb motor impairments and disrupts forelimb movement representations within the motor cortex. <b>2011</b> , 1, 93-100		7
68	Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6-OHDA-lesioned rats. <b>2011</b> , 33, 2247-54		20
67	The relevance of iron in the pathogenesis of Parkinson's disease. <b>2011</b> , 118, 939-57		244
66	Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. <b>2011</b> , 18, 980-7		44
65	Determination of minimal clinically important change in early and advanced Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 813-8	7	107
64	The molecular basis of working mechanism of natural polyphenolic antioxidants. <b>2011</b> , 125, 288-306		717
63	Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease. <b>2011</b> , 27, 907-19		47
62	Phosphatidylinositol 3-kinase/Akt signaling pathway mediates acupuncture-induced dopaminergic neuron protection and motor function improvement in a mouse model of Parkinson's disease. <b>2011</b> , 121, 562-9		38
61	Different reactive oxygen species lead to distinct changes of cellular metal ions in the eukaryotic model organism <i>Saccharomyces cerevisiae</i> . <i>International Journal of Molecular Sciences</i> , <b>2011</b> , 12, 8119-32	6.3	11
60	Effect of single amino acid substitution on oxidative modifications of the Parkinson's disease-related protein, DJ-1. <b>2012</b> , 11, M111.010892		18
59	Motor profile and drug treatment of nursing home residents with Parkinson's disease. <b>2012</b> , 60, 2277-82		25
58	METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ROPINIROLE HCL IN TABLETS BY RP-HPLC. <b>2012</b> , 2,		
57	Parkinson's Disease. 215-226		
56	Rasagiline treatment effects on parkinsonian tremor. <b>2013</b> , 123, 859-65		7

55	Interaction between ropinirole hydrochloride and aspirin with human serum albumin as binary and ternary systems by multi-spectroscopic, molecular modeling and zeta potential. <b>2013</b> , 134, 758-771		24
54	Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. <b>2013</b> , 20, 180-7		9
53	Interaction of D $\beta$ -preferring agonist (-)-NE[2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl]-NE[propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D $\alpha$ , D $\beta$ , and D $\gamma$ receptors: potent stimulation of mitogen-activated protein kinases and G protein-coupled inward rectifier potassium channels. <b>2013</b> , 386, 97-105		4
52	Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. <i>Journal of Drug Targeting</i> , <b>2013</b> , 21, 354-66	5.4	36
51	Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. <i>Contemporary Clinical Trials</i> , <b>2013</b> , 36, 90-8	2.3	18
50	Treatment in early Parkinson's disease: the Norwegian ParkWest study. <i>Acta Neurologica Scandinavica</i> , <b>2013</b> , 128, 107-13	3.8	4
49	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , <b>2013</b> , 27, 81-95	3.1	17
48	HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. <i>Frontiers in Pharmacology</i> , <b>2014</b> , 5, 165	5.6	29
47	Initial management of Parkinson's disease. <i>BMJ, The</i> , <b>2014</b> , 349, g6258	5.9	43
46	Dopamine receptor agonists for Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 387-410	5.9	31
45	Brain iron metabolism and brain injury following subarachnoid hemorrhage: iCeFISH-pilot (CSF iron in SAH). <i>Neurocritical Care</i> , <b>2014</b> , 21, 285-93	3.3	25
44	Early versus delayed initiation of pharmacotherapy in Parkinson's disease. <i>Drugs</i> , <b>2014</b> , 74, 645-57	12.1	11
43	Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20, 142-8	3.6	69
42	Evidence-based treatment of Parkinson's disease. <b>2015</b> , 191-208		
41	. <b>2015</b> ,		2
40	Korean Red Ginseng protects dopaminergic neurons by suppressing the cleavage of p35 to p25 in a Parkinson's disease mouse model. <i>Journal of Ginseng Research</i> , <b>2015</b> , 39, 148-54	5.8	22
39	R2* mapping for brain iron: associations with cognition in normal aging. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 925-32	5.6	84
38	In Vitro and in Vivo Neuroprotective Effects of Walnut (Juglandis Semen) in Models of Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	14

37	Noninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson's Disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 19579	4.9	73
36	Pre-treatment of rats with ad-hepcidin prevents iron-induced oxidative stress in the brain. <i>Free Radical Biology and Medicine</i> , <b>2016</b> , 90, 126-32	7.8	30
35	C282Y and H63D Polymorphisms in Hemochromatosis Gene and Risk of Parkinson's Disease: A Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , <b>2016</b> , 31, 201-7	2.5	5
34	Novel tactics for neuroprotection in Parkinson's disease: Role of antibiotics, polyphenols and neuropeptides. <i>Progress in Neurobiology</i> , <b>2017</b> , 155, 120-148	10.9	104
33	Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis. <i>Scientific Reports</i> , <b>2017</b> , 8, 45865	4.9	19
32	Therapeutic Strategies in Neurodegenerative Diseases. <b>2017</b> , 681-711		
31	Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats. <i>Molecular Neurobiology</i> , <b>2017</b> , 54, 5213-5224	6.2	49
30	A novel cesium modified carbon paste electrode for rapid selective determination of ropinirole in presence of co-administered and interference substances. <i>Sensors and Actuators B: Chemical</i> , <b>2017</b> , 240, 1291-1301	8.5	17
29	Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson's Disease. <i>Journal of Clinical Medicine</i> , <b>2017</b> , 6,	5.1	33
28	Parkinson's Disease. <b>2017</b> , 241-269		
27	Non-human primate models of PD to test novel therapies. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 291-324	4.3	26
26	Nervous System Injury in Response to Contact With Environmental, Engineered and Planetary Micro- and Nano-Sized Particles. <i>Frontiers in Physiology</i> , <b>2018</b> , 9, 728	4.6	27
25	Comparison of Actions between L-DOPA and Different Dopamine Agonists in Striatal DA-Depleted Microcircuits In Vitro: Pre-Clinical Insights. <i>Neuroscience</i> , <b>2019</b> , 410, 76-96	3.9	4
24	Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies. <i>Psychogeriatrics</i> , <b>2019</b> , 19, 345-354	1.8	
23	Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction. <i>BMC Veterinary Research</i> , <b>2020</b> , 16, 356	2.7	2
22	A blinded, controlled trial of objective measurement in Parkinson's disease. <i>Npj Parkinson's Disease</i> , <b>2020</b> , 6, 35	9.7	9
21	Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder. <i>Brain</i> , <b>2020</b> , 143, 2502-2518	11.2	16
20	Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD). <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1331-1338	6.4	3

19	Evaluation of Prescription Practices of Domperidone in Parkinson's Disease: A Cross Sectional Study Among French Neurologists. <i>CNS Drugs</i> , <b>2020</b> , 34, 1267-1274	6.7	
18	N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 88	4.1	9
17	Red nucleus structure and function: from anatomy to clinical neurosciences. <i>Brain Structure and Function</i> , <b>2021</b> , 226, 69-91	4	13
16	Oral Levodopa Formulation Does Not Affect Progression of Parkinson Disease. <i>Clinical Neuropharmacology</i> , <b>2021</b> , 44, 47-52	1.4	
15	Emerging Pharmacotherapies for Motor Symptoms in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , <b>2021</b> , 34, 263-273	3.8	1
14	Transplantation in Parkinson's disease: The future looks bright. <i>Advances in Experimental Medicine and Biology</i> , <b>2006</b> , 557, 221-48	3.6	4
13	Measurements in vivo of parameters pertinent to ROS/RNS using EPR spectroscopy. <b>2002</b> , 341-357		2
12	CHAPTER 6:D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents. <i>RSC Drug Discovery Series</i> , <b>2013</b> , 126-148	0.6	1
11	Recent advances in the drug treatment of Parkinson's disease. <i>Current Opinion in Neurology</i> , <b>1999</b> , 12, 411-5	7.1	2
10	Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. <i>PLoS ONE</i> , <b>2010</b> , 5, e11838	3.7	106
9	Pro- and antioxidant systems and pathological processes in humans. <i>Visnik Nacional Noi Akademii Nauk Ukraini</i> , <b>2014</b> , 17-29	0.3	4
8	The Main Targets Involved in Neuroprotection for the Treatment of Alzheimer's Disease and Parkinson Disease. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 509-516	3.3	4
7	Overview of Therapeutic Drugs and Methods for the Treatment of Parkinson's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , <b>2020</b> , 19, 195-206	2.6	3
6	The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson's disease: a systematic review and meta-analysis. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	
5	Therapieempfehlungen der Früh- und Spätphase der Parkinson-Krankheit. <b>1999</b> , 335-355		
4	Klinik Ābrale Medikation. <b>1999</b> , 241-253		
3	Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?. <i>Journal of Neural Transmission Supplementum</i> , <b>1999</b> , 55, 33-45		13
2	Beneficial Effects of Spirulina Consumption on Brain Health.. <i>Nutrients</i> , <b>2022</b> , 14,	6.7	4

- 1 Psychosis in nursing home patients with Parkinson's disease. *Journal of the American Medical Directors Association*, **2004**, 5, 167-73

5.9 3